Sema4 Holdings Corp.

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BTSGU has a market cap of 37.5B. Regarding current trading prices, SMFR is priced at $0.31, while BTSGU trades at $193.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to BTSGU's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BTSGU's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, GEHC has a market cap of 28.5B. Regarding current trading prices, SMFR is priced at $0.31, while GEHC trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 15.03. In terms of profitability, SMFR's ROE is -0.28%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SMFR is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GEHC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, VEEV has a market cap of 25.5B. Regarding current trading prices, SMFR is priced at $0.31, while VEEV trades at $156.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas VEEV's P/E ratio is 28.74. In terms of profitability, SMFR's ROE is -0.28%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check VEEV's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SMFR is priced at $0.31, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, SMFR is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GEHCV's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BTSG has a market cap of 11.3B. Regarding current trading prices, SMFR is priced at $0.31, while BTSG trades at $58.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BTSG's P/E ratio is 75.84. In terms of profitability, SMFR's ROE is -0.28%, compared to BTSG's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BTSG's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SMFR is priced at $0.31, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SMFR's ROE is -0.28%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SMFR is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SGFY's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, TEM has a market cap of 7.9B. Regarding current trading prices, SMFR is priced at $0.31, while TEM trades at $45.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas TEM's P/E ratio is -26.44. In terms of profitability, SMFR's ROE is -0.28%, compared to TEM's ROE of -0.70%. Regarding short-term risk, SMFR is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TEM's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HQY has a market cap of 7B. Regarding current trading prices, SMFR is priced at $0.31, while HQY trades at $82.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HQY's P/E ratio is 33.46. In terms of profitability, SMFR's ROE is -0.28%, compared to HQY's ROE of +0.10%. Regarding short-term risk, SMFR is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HQY's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SMFR is priced at $0.31, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas RCM's P/E ratio is -102.21. In terms of profitability, SMFR's ROE is -0.28%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SMFR is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check RCM's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HNGE has a market cap of 4.2B. Regarding current trading prices, SMFR is priced at $0.31, while HNGE trades at $53.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HNGE's P/E ratio is -6.04. In terms of profitability, SMFR's ROE is -0.28%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, SMFR is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HNGE's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SMFR is priced at $0.31, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SMFR's ROE is -0.28%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SMFR is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ONEM's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, DOCS has a market cap of 3.4B. Regarding current trading prices, SMFR is priced at $0.31, while DOCS trades at $18.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas DOCS's P/E ratio is 15.12. In terms of profitability, SMFR's ROE is -0.28%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, SMFR is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check DOCS's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PRVA has a market cap of 2.9B. Regarding current trading prices, SMFR is priced at $0.31, while PRVA trades at $23.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PRVA's P/E ratio is 136.71. In terms of profitability, SMFR's ROE is -0.28%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, SMFR is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PRVA's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HTFL has a market cap of 2.8B. Regarding current trading prices, SMFR is priced at $0.31, while HTFL trades at $32.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HTFL's P/E ratio is -10.17. In terms of profitability, SMFR's ROE is -0.28%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, SMFR is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HTFL's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, TXG has a market cap of 2.7B. Regarding current trading prices, SMFR is priced at $0.31, while TXG trades at $21.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -126.59. In terms of profitability, SMFR's ROE is -0.28%, compared to TXG's ROE of -0.03%. Regarding short-term risk, SMFR is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TXG's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SMFR is priced at $0.31, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PINC's P/E ratio is 166.24. In terms of profitability, SMFR's ROE is -0.28%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SMFR is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PINC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, OMCL has a market cap of 2B. Regarding current trading prices, SMFR is priced at $0.31, while OMCL trades at $43.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas OMCL's P/E ratio is 99.55. In terms of profitability, SMFR's ROE is -0.28%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, SMFR is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OMCL's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, SMFR is priced at $0.31, while PGNY trades at $22.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PGNY's P/E ratio is 29.70. In terms of profitability, SMFR's ROE is -0.28%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PGNY's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SMFR is priced at $0.31, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SMFR's ROE is -0.28%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SMFR is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NXGN's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SMFR is priced at $0.31, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SMFR's ROE is -0.28%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SMFR is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AGTI's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, SMFR is priced at $0.31, while TDOC trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas TDOC's P/E ratio is -0.23. In terms of profitability, SMFR's ROE is -0.28%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, SMFR is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TDOC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, WGS has a market cap of 1.2B. Regarding current trading prices, SMFR is priced at $0.31, while WGS trades at $38.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas WGS's P/E ratio is -14.61. In terms of profitability, SMFR's ROE is -0.28%, compared to WGS's ROE of -0.28%. Regarding short-term risk, SMFR is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check WGS's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, OMDA has a market cap of 985.7M. Regarding current trading prices, SMFR is priced at $0.31, while OMDA trades at $16.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas OMDA's P/E ratio is -66.32. In terms of profitability, SMFR's ROE is -0.28%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, SMFR is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OMDA's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SDGR has a market cap of 943M. Regarding current trading prices, SMFR is priced at $0.31, while SDGR trades at $12.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SDGR's P/E ratio is -9.01. In terms of profitability, SMFR's ROE is -0.28%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, SMFR is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SDGR's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, GDRX has a market cap of 863.1M. Regarding current trading prices, SMFR is priced at $0.31, while GDRX trades at $2.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas GDRX's P/E ratio is 41.50. In terms of profitability, SMFR's ROE is -0.28%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, SMFR is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GDRX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLDO has a market cap of 857.6M. Regarding current trading prices, SMFR is priced at $0.31, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLDO's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, NUTX has a market cap of 761.2M. Regarding current trading prices, SMFR is priced at $0.31, while NUTX trades at $127.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 9.35. In terms of profitability, SMFR's ROE is -0.28%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, SMFR is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NUTX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CERT has a market cap of 717.2M. Regarding current trading prices, SMFR is priced at $0.31, while CERT trades at $4.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CERT's P/E ratio is -46.10. In terms of profitability, SMFR's ROE is -0.28%, compared to CERT's ROE of -0.01%. Regarding short-term risk, SMFR is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CERT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HSTM has a market cap of 665.8M. Regarding current trading prices, SMFR is priced at $0.31, while HSTM trades at $22.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HSTM's P/E ratio is 34.01. In terms of profitability, SMFR's ROE is -0.28%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, SMFR is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HSTM's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SMFR is priced at $0.31, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, SMFR is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check MPLN-WT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SMFR is priced at $0.31, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SMFR's ROE is -0.28%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SMFR is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ACCD's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PHR has a market cap of 532.3M. Regarding current trading prices, SMFR is priced at $0.31, while PHR trades at $8.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PHR's P/E ratio is 219.00. In terms of profitability, SMFR's ROE is -0.28%, compared to PHR's ROE of +0.01%. Regarding short-term risk, SMFR is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PHR's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SMFR is priced at $0.31, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SMFR's ROE is -0.28%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SMFR is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHCR's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, EVH has a market cap of 461.2M. Regarding current trading prices, SMFR is priced at $0.31, while EVH trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas EVH's P/E ratio is -0.88. In terms of profitability, SMFR's ROE is -0.28%, compared to EVH's ROE of -0.78%. Regarding short-term risk, SMFR is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check EVH's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, NRC has a market cap of 426.6M. Regarding current trading prices, SMFR is priced at $0.31, while NRC trades at $18.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas NRC's P/E ratio is 48.54. In terms of profitability, SMFR's ROE is -0.28%, compared to NRC's ROE of +0.57%. Regarding short-term risk, SMFR is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NRC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CTEV has a market cap of 400M. Regarding current trading prices, SMFR is priced at $0.31, while CTEV trades at $23.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CTEV's P/E ratio is -1.35. In terms of profitability, SMFR's ROE is -0.28%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, SMFR is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CTEV's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SMFR is priced at $0.31, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SMFR's ROE is -0.28%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SMFR is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SLGC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SMFR is priced at $0.31, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SMFR's ROE is -0.28%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SMFR is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check SLGCW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, TBRG has a market cap of 387.6M. Regarding current trading prices, SMFR is priced at $0.31, while TBRG trades at $25.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas TBRG's P/E ratio is 89.10. In terms of profitability, SMFR's ROE is -0.28%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SMFR is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TBRG's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SY has a market cap of 375M. Regarding current trading prices, SMFR is priced at $0.31, while SY trades at $2.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SY's P/E ratio is -8.14. In terms of profitability, SMFR's ROE is -0.28%, compared to SY's ROE of -0.14%. Regarding short-term risk, SMFR is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SY's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SMFR is priced at $0.31, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SMFR's ROE is -0.28%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, SMFR is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MPLN's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SOPH has a market cap of 339.7M. Regarding current trading prices, SMFR is priced at $0.31, while SOPH trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SOPH's P/E ratio is -4.02. In terms of profitability, SMFR's ROE is -0.28%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, SMFR is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SOPH's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CARL has a market cap of 292.5M. Regarding current trading prices, SMFR is priced at $0.31, while CARL trades at $10.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CARL's P/E ratio is -11.09. In terms of profitability, SMFR's ROE is -0.28%, compared to CARL's ROE of -0.62%. Regarding short-term risk, SMFR is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CARL's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SMFR is priced at $0.31, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SMFR's ROE is -0.28%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SMFR is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TRHC's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLP has a market cap of 270.3M. Regarding current trading prices, SMFR is priced at $0.31, while SLP trades at $13.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SLP's P/E ratio is -4.29. In terms of profitability, SMFR's ROE is -0.28%, compared to SLP's ROE of -0.49%. Regarding short-term risk, SMFR is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SLP's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SPOK has a market cap of 228.3M. Regarding current trading prices, SMFR is priced at $0.31, while SPOK trades at $10.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SPOK's P/E ratio is 18.53. In terms of profitability, SMFR's ROE is -0.28%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, SMFR is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SPOK's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SMFR is priced at $0.31, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SMFR's ROE is -0.28%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SMFR is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CPSI's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, AMWL has a market cap of 129.8M. Regarding current trading prices, SMFR is priced at $0.31, while AMWL trades at $7.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas AMWL's P/E ratio is -1.43. In terms of profitability, SMFR's ROE is -0.28%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, SMFR is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AMWL's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SMFR is priced at $0.31, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SMFR's ROE is -0.28%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SMFR is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AUGX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, OPRX has a market cap of 97.2M. Regarding current trading prices, SMFR is priced at $0.31, while OPRX trades at $5.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas OPRX's P/E ratio is 14.39. In terms of profitability, SMFR's ROE is -0.28%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, SMFR is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OPRX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLD has a market cap of 90.9M. Regarding current trading prices, SMFR is priced at $0.31, while CCLD trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CCLD's P/E ratio is 16.46. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLD's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, DH has a market cap of 90.8M. Regarding current trading prices, SMFR is priced at $0.31, while DH trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas DH's P/E ratio is -0.51. In terms of profitability, SMFR's ROE is -0.28%, compared to DH's ROE of -0.67%. Regarding short-term risk, SMFR is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check DH's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HCAT has a market cap of 86.5M. Regarding current trading prices, SMFR is priced at $0.31, while HCAT trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HCAT's P/E ratio is -0.31. In terms of profitability, SMFR's ROE is -0.28%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, SMFR is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HCAT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, FORA has a market cap of 67.9M. Regarding current trading prices, SMFR is priced at $0.31, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas FORA's P/E ratio is -24.17. In terms of profitability, SMFR's ROE is -0.28%, compared to FORA's ROE of -0.09%. Regarding short-term risk, SMFR is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check FORA's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SMFR is priced at $0.31, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLDP's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BEAT has a market cap of 35.8M. Regarding current trading prices, SMFR is priced at $0.31, while BEAT trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BEAT's P/E ratio is -1.68. In terms of profitability, SMFR's ROE is -0.28%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, SMFR is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BEAT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SMFR is priced at $0.31, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SMFR's ROE is -0.28%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SMFR is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SNCE's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SMFR is priced at $0.31, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SMFR's ROE is -0.28%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SMFR is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AKLI's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SMFR is priced at $0.31, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SMFR's ROE is -0.28%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SMFR is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHLT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SMFR is priced at $0.31, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SMFR is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHCRW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ONMD has a market cap of 31M. Regarding current trading prices, SMFR is priced at $0.31, while ONMD trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ONMD's P/E ratio is -15.75. In terms of profitability, SMFR's ROE is -0.28%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, SMFR is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ONMD's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, EUDA has a market cap of 27M. Regarding current trading prices, SMFR is priced at $0.31, while EUDA trades at $14.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -9.77. In terms of profitability, SMFR's ROE is -0.28%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check EUDA's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SMFR is priced at $0.31, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas STRM's P/E ratio is -2.40. In terms of profitability, SMFR's ROE is -0.28%, compared to STRM's ROE of -0.32%. Regarding short-term risk, SMFR is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check STRM's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SMFR is priced at $0.31, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SMFR's ROE is -0.28%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SMFR is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check RNLX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SMFR is priced at $0.31, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SMFR is priced at $0.31, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SMFR's ROE is -0.28%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SMFR is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BBLN's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SMFR is priced at $0.31, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SMFR's ROE is -0.28%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SMFR is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check ETAO's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SMFR is priced at $0.31, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SMFR is more volatile compared to HLTH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HLTH's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BFRG has a market cap of 6.5M. Regarding current trading prices, SMFR is priced at $0.31, while BFRG trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BFRG's P/E ratio is -0.98. In terms of profitability, SMFR's ROE is -0.28%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, SMFR is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BFRG's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, SMFR is priced at $0.31, while SCNX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.15. In terms of profitability, SMFR's ROE is -0.28%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, SMFR is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SCNX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SMFR is priced at $0.31, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SMFR is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check UPH-WT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SMFR is priced at $0.31, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas UPH's P/E ratio is -0.07. In terms of profitability, SMFR's ROE is -0.28%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SMFR is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check UPH's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ZCMD has a market cap of 4.8M. Regarding current trading prices, SMFR is priced at $0.31, while ZCMD trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ZCMD's P/E ratio is -0.80. In terms of profitability, SMFR's ROE is -0.28%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SMFR is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ZCMD's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MGRX has a market cap of 4.2M. Regarding current trading prices, SMFR is priced at $0.31, while MGRX trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MGRX's P/E ratio is -0.19. In terms of profitability, SMFR's ROE is -0.28%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, SMFR is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MGRX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SMFR is priced at $0.31, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SMFR's ROE is -0.28%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SMFR is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check PEAR's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SMFR is priced at $0.31, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SMFR is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check PEARW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, VSEE has a market cap of 2.9M. Regarding current trading prices, SMFR is priced at $0.31, while VSEE trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas VSEE's P/E ratio is -0.24. In terms of profitability, SMFR's ROE is -0.28%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, SMFR is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check VSEE's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BFRGW has a market cap of 2.8M. Regarding current trading prices, SMFR is priced at $0.31, while BFRGW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, SMFR is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BFRGW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, HCTI has a market cap of 2.6M. Regarding current trading prices, SMFR is priced at $0.31, while HCTI trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas HCTI's P/E ratio is -0.01. In terms of profitability, SMFR's ROE is -0.28%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, SMFR is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HCTI's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, BEATW has a market cap of 2.5M. Regarding current trading prices, SMFR is priced at $0.31, while BEATW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas BEATW's P/E ratio is -0.15. In terms of profitability, SMFR's ROE is -0.28%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, SMFR is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BEATW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SMFR is priced at $0.31, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, SMFR is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OTRK's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACON has a market cap of 1.7M. Regarding current trading prices, SMFR is priced at $0.31, while ACON trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ACON's P/E ratio is -0.24. In terms of profitability, SMFR's ROE is -0.28%, compared to ACON's ROE of -0.00%. Regarding short-term risk, SMFR is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ACON's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SMFR is priced at $0.31, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SMFR is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CMAX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, EUDAW has a market cap of 1.4M. Regarding current trading prices, SMFR is priced at $0.31, while EUDAW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, SMFR is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check EUDAW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, VSEEW has a market cap of 1.3M. Regarding current trading prices, SMFR is priced at $0.31, while VSEEW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, SMFR is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check VSEEW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SMFR is priced at $0.31, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFWZ's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SMFR is priced at $0.31, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SMFR is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check MSPRZ's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MSPR has a market cap of 423.3K. Regarding current trading prices, SMFR is priced at $0.31, while MSPR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MSPR's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to MSPR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MSPR's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, SMFR is priced at $0.31, while WORX trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas WORX's P/E ratio is -0.12. In terms of profitability, SMFR's ROE is -0.28%, compared to WORX's ROE of -0.73%. Regarding short-term risk, SMFR is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check WORX's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, WGSWW has a market cap of 167.8K. Regarding current trading prices, SMFR is priced at $0.31, while WGSWW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, SMFR is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check WGSWW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SMFR is priced at $0.31, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, SMFR is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check KERNW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SMFR is priced at $0.31, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas KERN's P/E ratio is -0.01. In terms of profitability, SMFR's ROE is -0.28%, compared to KERN's ROE of -0.17%. Regarding short-term risk, SMFR is more volatile compared to KERN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check KERN's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SMFR is priced at $0.31, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFWW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, SMFR is priced at $0.31, while OTRKP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, SMFR is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check OTRKP's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SMFR is priced at $0.31, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SMFR is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CMAXW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACONW has a market cap of 17.3K. Regarding current trading prices, SMFR is priced at $0.31, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ACONW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, SMFR is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ACONW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, SMFR is priced at $0.31, while ICCT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas ICCT's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, SMFR is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ICCT's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, SMFR is priced at $0.31, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MSPRW's competition here

SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMFR stands at 246.4M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, SMFR is priced at $0.31, while FOXO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMFR currently has a P/E ratio of N/A, whereas FOXO's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to FOXO's ROE of -0.91%. Regarding short-term risk, SMFR is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check FOXO's competition here